Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Reshaping Cystic Fibrosis Disease Landscape Report | Epidemiology Study, Drug Insights, Unmet Needs Analysis, KOL Perspectives Product Launch Services, and Regulatory Consulting |Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

09 Oct, 2023, 09:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Oct. 9, 2023 /PRNewswire/ -- Cystic Fibrosis has affecting a large portion of the global population.  According to an epidemiology study conducted by the American Lung Association, nearly 70,000 individuals worldwide are presently living with this dreadful disease. Although there is no permanent cure for it, but numerous cystic fibrosis treatment solutions have been developed so far.

Cystic fibrosis is a genetic disorder triggered by CFTR gene mutations, leading to the production of sticky and thick mucus in various parts of the body. It mostly affects the pancreas and lungs. There was a time when cystic fibrosis life expectancy was very low and most of the patients could not make it. But now with widespread medical advancements, many individuals can now live well into adulthood and lead fulfilling lives.

DiseaseLandscape Insights has been providing the players with disease insights, allowing them to understand the characteristics, traits, and cystic fibrosis symptoms comprehensively. They are leveraging DLI's healthcare consulting services to accelerated their cystic fibrosis research & development activities. This health consultant is also helping them with clinical trial management, market entry strategy, product portfolio extension, treatment gaps identification, along with pricing and market access related decisions.

Price and Market Access

Disease Overview:

Major symptoms:

Cystic fibrosis (CF) is characterized by a range of major symptoms that primarily affect the respiratory and digestive systems. Common respiratory symptoms include persistent cough, wheezing, recurrent respiratory infections, and shortness of breath due to the production of thick and sticky mucus in the airways. Digestive symptoms involve malabsorption of nutrients, leading to weight loss, greasy stools, malnutrition, and digestive discomfort due to blockages in the pancreas ducts. Additionally, individuals with CF may experience salt imbalances, resulting in excessive salt in their sweat. Early diagnosis and proactive management are essential to address these major symptoms and improve the quality of life for those with CF.

Diagnostic Market Players:

The Market Competitors Listed Below are Revolutionizing Healthcare with Innovative Diagnostic Inventions:

Blood Test- 

  • Roche Ltd.
  • Sun Pharmaceuticals Industries Ltd
  • Cipla Limited
  • Thyrocare Technologies
  • Dr. Reddy's Laboratory,
  • Dr. Lal Path labs, Fortis Healthcare

Genetic Test-

  • IntegraGen
  • Abbott
  • AutoGenomics
  • Biocartis
  • Bio – Rad laboratories
  • Cepheid,
  • Elitech Group

Imaging Test- 

  • GE Healthcare
  • Radiance Imaging System
  • Hitachi Ltd.
  • Med Imaging Solutions
  • DiagnoTech Corporation
  • Siemens Healthineers
  • Esaote S.p.A.

Learn More About the FDA NDA & BLA Approval (NME) Drugs for Cystic fibrosis Disease@

Request_Cystic Fibrosis Disease

Diagnosis and Treatment:

Cystic fibrosis is diagnosed through a combination of tests, including newborn screening to detect elevated immunoreactive trypsinogen (IRT) levels, followed by a sweat test to confirm the diagnosis by measuring salt levels in sweat. Genetic testing further identifies specific CFTR gene mutations involved. Several other tests are also conducted to check for mucus build-up, lung disease, and other related symptoms.

Early detection paves the way for fast cystic fibrosis prognosis which is live saving for many. With extensive R&D advancements various drugs and therapies have been introduced. The treatment of cystic fibrosis involves a multifaceted approach, including gene therapy, physiotherapy, airway clearance techniques, FDA approved medications like bronchodilators, mucolytics, and antibiotics, nutritional support to maintain adequate calories and nutrients, potential enzyme replacement therapy for pancreatic insufficiency, pulmonary rehabilitation, psychosocial support, and regular monitoring by a specialized CF care team to adapt treatment plans as needed for each individual's unique needs.

With increased disease burden, the related players are seeking pharma consulting services from DLI. The latter has been assisting them with clinical trial feasibility analysis, new product development services, post launch services, regulatory consulting, along with commercial strategy analysis, among others.

Unlock the Benefits Today! Get Started Now and Elevate Your Experience @

Checkout_Cystic Fibrosis Disease

Final Words:

Cystic fibrosis is a complex genetic disorder that affects the respiratory and digestive systems, leading to significant challenges for individuals living with the condition. DLI has been playing pivotal role in reshaping our understanding and approach to cystic fibrosis. These insights encompass epidemiological studies, drug research and development, product launch services, and regulatory consulting. By leveraging DLIs, we gain a deeper understanding of CF's prevalence, its evolving treatment landscape, and the regulatory pathways required for new therapies. This collective knowledge empowers researchers, healthcare providers, policymakers, and patient advocacy groups to collaborate effectively, advance innovative treatments, and ultimately improve the lives of those impacted by cystic fibrosis. With continued efforts and the integration of DLIs, we can aspire to enhance the quality of care, extend life expectancy, and bring hope to individuals and families affected by this challenging condition.

Browse Through More Genetic Diseases Research Reports

Related Reports:

Solid Tumor Diseases: A Comprehensive Guide to Detection and Therapeutic Strategies

Demodex Blepharitis: Diagnosis, Treatment, and Prevention

Duchenne Muscular Dystrophy (DMD): A Comprehensive Guide for Patients and Families

Hemophilia Disease Explained: Causes, Symptoms, and Treatment Options

Spinal Muscular Atrophy (SMA) Disease Chronicles: Navigating Life with Spinal Muscular Atrophy

Predictive analytics powered by AI: Unlocking Insights for the Future of Healthcare.

Natural Language Processing (NLP) in Healthcare: Unlocking the Potential.

Posluma: A Targeted Oncology Cutting-Edge Advancement in Prostate Cancer Imaging.

Fezolinetant by Veozah: Advancing Women's Health by Astellas Pharma Inc.

A Glimmer of Hope for Migraine Sufferers: Zavzpret.

Rethinking Treatment Options for a Better Future with Hemophilia Gene Therapy.

Reach New Heights with Mass Production of Benzathine Penicillin G as We Overcome the Challenge.

 Case study on the development of novel medications.

Case Study: Software Application for Personalized Care with Data-Driven Insights.

Case Study: Cancer Vaccine Targeting an Antigen.

Case Study: Lung Cancer Immunotherapy Combination Trials.

software implementation for inventory and supply chain management.

Asset scouting for cystic fibrosis.

The Successful Commercialization of a Revolutionary Non-Invasive Glucose Monitoring Device after Regulatory Approval.

Investing in pancreatic cancer chemotherapy drugs.

About Disease Landscape:  

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:  
Disease Landscape Insights LLP  
6th Floor, Sr No.207, Office A H 6070 Phase 1 
Solitaire Business Hub, Viman Nagar 
Pune, Maharashtra, 411014 
Email: ajay@diseaselandscape.com    
Email: vishal@diseaselandscape.com
Sales: +44-2038074155 
Asia Office: +917447409162
Blog: https://www.diseaselandscape.com/blogs 
Case Study: https://www.diseaselandscape.com/casestudies  
Pharma consulting Services 
Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.